Contact

Dr. Nicole Berndt
Radioimmunology
n.berndtAthzdr.de

Prof. Dr. Michael Bachmann
Executive Director (alternating)
Radioimmunology
m.bachmannAthzdr.de
Phone: +49 351 260 - +49 351 458 2101, 2060, 3170, +49 172 694 8424
Fax: +49 351 260 - 3232

Combination of Immunotherapeutic Approaches with Conventional Tumor Therapies especially exogenous and endogenous Radiotherapy

Combination of Immunotherapeutics

Over the last years we developed and established numerous monoclonal antibodies as well as different humanized recombinant antibody formats including BiTEs, scFvs, nanobodies, peptide epitopes and target modules (e.g. peptide ligands based on tracers, PLT TM). Besides their role for cancer immunotherapeutic approaches, all these molecules can be radioactively labeled and therefore be used as diagnostic tools for tumor imaging, for monitoring of tumor therapies and/or for endoradionuclide therapy. In spite of tumor therapy in patients radiolabeled recombinant Ab molecules can be applied either alone or alongside with other tumor specific therapies e.g. exogenous radiotherapy. Most importantly, each molecule has to be optimized regarding its pharmacokinetic properties and the chosen radionuclide to allow precise tumor imaging and/or effective endoradionuclide therapy.

References:

Contact

Dr. Nicole Berndt
Radioimmunology
n.berndtAthzdr.de

Prof. Dr. Michael Bachmann
Executive Director (alternating)
Radioimmunology
m.bachmannAthzdr.de
Phone: +49 351 260 - +49 351 458 2101, 2060, 3170, +49 172 694 8424
Fax: +49 351 260 - 3232